1021000
USP
Aminocaproic acid
United States Pharmacopeia (USP) Reference Standard
Synonym(s):
6-Aminocaproic acid, ε-Aminocaproic acid, 6-Aminohexanoic acid, EACA
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Linear Formula:
H2N(CH2)5CO2H
CAS Number:
Molecular Weight:
131.17
Beilstein:
906872
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24
Recommended Products
grade
pharmaceutical primary standard
API family
aminocaproic acid
form
fine crystals
powder
manufacturer/tradename
USP
mp
207-209 °C (dec.) (lit.)
density
1.042 g/cm3
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
SMILES string
NCCCCCC(O)=O
InChI
1S/C6H13NO2/c7-5-3-1-2-4-6(8)9/h1-5,7H2,(H,8,9)
InChI key
SLXKOJJOQWFEFD-UHFFFAOYSA-N
Gene Information
human ... PLAT(5327) , PLG(5340)
Looking for similar products? Visit Product Comparison Guide
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Aminocaproic acid USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Aminocaproic Acid Injection
- Aminocaproic Acid Oral Solution
- Aminocaproic Acid Tablets
Biochem/physiol Actions
Lysine analog. Promotes rapid dissociation of plasmin, thereby inhibiting the activation of plasminogen and subsequent fibrinolysis. Reported to inhibit plasminogen binding to activated platelets. An early report indicated that it inhibits the activation of the first component of the complement system. Binds and inactivates Carboxypeptidase B.
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
related product
Product No.
Description
Pricing
Storage Class Code
11 - Combustible Solids
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Nabaneeta Mukhopadhyay et al.
Physical chemistry chemical physics : PCCP, 17(6), 4293-4310 (2015-01-13)
Blends of polypropylene (PP) and polyamide 6 (PA6) with multiwalled carbon nanotubes (MWNTs) were prepared using different processing strategies in a twin-screw micro-compounder. The effect of MWNTs on the crystallization behaviour of the PP phase and the PA6 phase of
Kun Shao et al.
Advanced healthcare materials, 4(2), 291-300 (2014-08-16)
Due to complication factors such as blood-brain barrier (BBB), integrating high efficiency of brain target ability with specific cargo releasing into one nanocarrier seems more important. A brain targeting nanoscale system is developed using dehydroascorbic acid (DHA) as targeting moiety.
Sylvie Bannwarth et al.
Brain : a journal of neurology, 137(Pt 8), 2329-2345 (2014-06-18)
Mitochondrial DNA instability disorders are responsible for a large clinical spectrum, among which amyotrophic lateral sclerosis-like symptoms and frontotemporal dementia are extremely rare. We report a large family with a late-onset phenotype including motor neuron disease, cognitive decline resembling frontotemporal
María de los Angeles Serrano et al.
Zygote (Cambridge, England), 23(1), 99-110 (2013-07-31)
The objective of this study was to elucidate the signalling pathways initiated by cAMP once inside the Xenopus laevis oocyte, where it triggers and maintains vitellogenin endocytic uptake. Our results showed the presence of Xepac transcripts at all stages of
Rameshwar R Rao et al.
Tissue engineering. Part A, 21(3-4), 530-540 (2014-09-18)
Minimally invasive, injectable bone tissue engineering therapies offer the potential to facilitate orthopedic repair procedures, including in indications where enhanced bone regeneration is needed for complete healing. In this study, we developed a dual-phase tissue construct consisting of osteogenic (Osteo)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service